Skip to main content

Table 3 Efficacy endpoints after the third and sixth monthly erenumab administrations (n = 70)

From: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

Outcomes Baseline Administration
Third Sixth
Reduction from baseline in MHD
  ≥ 30%   49 (70) 56 (80)
  ≥ 50%   37 (53) 49 (70)
  ≥ 75%   13 (18) 18 (26)
Response after dose increase in non-responder patients 6/21 (29)
MHD 21.1 ± 0.7 11.4 ± 0.9* 8.9 ± 0.7*
Conversion from chronic to episodic migraine 46 (66) 49 (70)
Conversion from medication overuse to non-overuse 40 (57) 43 (62)
Pain intensity (NRS) 8.6 ± 0.1 8.1 ± 0.1* 7.9 ± 0.1*
MIDAS 108.1 ± 11.2 54.5 ± 11.4* 51.0 ± 9.7*
HIT-6 65.9 ± 1.2 60.7 ± 1.2* 59.5 ± 1.4*
MSQ 62.7 ± 7.5 42.0 ± 7.6* 41.5 ± 7.7*
BDI-II 17.0 ± 1.4 13.2 ± 1.5 11.2 ± 1.6*
HDRS 14.3 ± 0.9 12.3 ± 1.5 10.5 ± 1.2*
HARS 17.1 ± 1.2 15.1 ± 1.7 13.2 ± 1.6*
PCS 33.2 ± 1.3 24.9 ± 1.8* 25.8 ± 2.1*
MOS Sleep Scale 24.7 ± 0.7 24.2 ± 0.8 22.9 ± 1.1*
ASC-12 6.7 ± 0.7 5.5 ± 0.8* 4.8 ± 0.8*
MIG-SCOG 9.9 ± 0.6 8.6 ± 0.6 8.8 ± 0.8
  1. Values are mean ± standard error (SE) or number (%)
  2. * statistically significant difference (in comparison with baseline)
  3. ASC-12 Allodynia Symptom Checklist-12, BDI II Beck Depression Inventory II, HARS, Hamilton Anxiety Rating Scale, HDRS Hamilton Depression Rating Scale, HIT-6 headache impact test-6, MIDAS migraine disability assessment scale, MIG-SCOG MIGraine attacks - Subjective COGnitive impairments scale, MHD monthly headache days, MOH medication overuse headache, MOS Medical Outcomes Study, MSQ migraine-specific quality-of-life questionnaire, NRS numerical rating scale, PCS Pain Catastrophizing Scale
\